The arrival of respiratory illnesses, including respiratory syncytial virus (RSV), is a common occurrence during this time of year. RSV symptoms in mild cases can resemble a common cold, with symptoms like a runny nose, coughing, sneezing, wheezing, fever, decreased appetite, and fatigue. However, older adults and infants face a higher risk of severe outcomes, potentially leading to hospitalization.
This year, for the first time, a vaccine called Arexvy has become available to protect older adults (aged 60 and over) against RSV. Health Canada approved Arexvy in August, and it demonstrated nearly 83 percent efficacy in preventing lower respiratory tract disease caused by RSV and a 94 percent efficacy in preventing severe RSV-associated illness.
Many individuals have inquired about where to obtain the vaccine and its cost. Here is what we know:
Will my province or territory cover the cost?
The coverage depends on your location. Currently, Ontario is the only province publicly funding the RSV vaccine for some individuals over 60, including those in long-term care homes, elder care lodges, and some dementia care service-licensed retirement homes.
Provincial and territorial health authorities are waiting for guidance from the National Advisory Committee on Immunization (NACI) to decide whether to include Arexvy in publicly funded programs. The availability and terms of coverage vary across provinces and territories.
What’s it going to cost me?
If you must pay out-of-pocket, the cost of the vaccine ranges from $200 to $350, depending on your province or territory.
Why are some vaccines covered, but others aren’t?
The decision on vaccine coverage depends on provincial and territorial health authorities and their drug plans. In the absence of NACI guidance, some health authorities are hesitant to include Arexvy for this season. Coverage may change in the future based on provincial or territorial implementation of NACI’s guidance.
Should I get it?
Healthcare professionals recommend seniors eligible for the vaccine to get it due to the significant effectiveness of Arexvy against RSV. RSV has no specific treatment, making prevention through vaccination crucial.
In the U.S., research indicates that adults over 65 have the highest mortality risk from RSV, with a six to eight percent fatality rate among older adults hospitalized with RSV. The exact number of hospitalizations and deaths related to RSV in Canada among those aged 60 and older is not well-tracked.
When is the best time to get it?
It is advisable to get the RSV vaccine now, as RSV circulation typically occurs from November to May. Getting the vaccine now can provide protection for up to two or three seasons.
What are the side effects?
Common side effects of the RSV vaccine may include a sore arm, tiredness, and fatigue. These reactions indicate that your immune system is responding to the vaccine. It is advisable to schedule vaccination around significant events to avoid potential downtime. If you have received the shingles vaccine, you may experience a similar symptom profile since the RSV vaccine uses a similar adjuvant therapy.
Stay informed about the availability and coverage of the RSV vaccine in your province or territory to make an informed decision regarding vaccination.